KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $527.5 million.

  • Aurinia Pharmaceuticals' Liabilities and Shareholders Equity fell 397.43% to $527.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 243.27%. This contributed to the annual value of $550.6 million for FY2024, which is 47.13% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity stood at $527.5 million, which was down 397.43% from $502.6 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $555.0 million in Q3 2023 and a low of $360.1 million during Q3 2021
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $506.9 million (2022), whereas its average is $496.5 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 3893.58% in 2021 and then tumbled by 1334.4% in 2022.
  • Aurinia Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $543.4 million in 2021, then decreased by 13.34% to $470.9 million in 2022, then rose by 16.4% to $548.1 million in 2023, then grew by 0.47% to $550.6 million in 2024, then fell by 4.2% to $527.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $527.5 million in Q3 2025, compared to $502.6 million in Q2 2025 and $504.8 million in Q1 2025.